Here’s Why You Don’t Bet Against This Dividend King
Corroborated by 2 sources from 2 publishers
globalgeneral7h ago
TL;DR
Summary - Johnson & Johnson is reiterated as a buy, driven by pipeline progress and recent valuation correction. - Icotyde's early FDA approval and $8B peak sales potential could add 8% annual growth to JNJ's top line. - Consensus projects JNJ EPS CAGR of 8.9% (2026â2030), with forward P/E compressing from 20.8x to 14.8x.